Every 424B that Aprea Therapeutics, Inc. (APRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. files a prospectus supplement registering 5,503,556 shares of Common Stock for resale by selling stockholders. The supplement updates the Prospectus dated December 29, 2025 and reflects assignments of Common Warrants to Squadron Master Fund LP. The resale includes (i) 26,459 shares issued in a private placement, (ii) 2,596,564 shares underlying pre-funded warrants, (iii) 2,623,023 shares underlying common stock purchase warrants, and (iv) 257,510 shares underlying warrants issued as placement compensation. The filing states there were 12,382,776 shares outstanding as of May 13, 2026. The supplement shows, including Squadron Master Fund LP: 536,480 shares listed as being offered, with post-offering beneficial ownership reported as 1,433,878 shares (9.99%).
Aprea Therapeutics, Inc. is registering 74,349,426 shares of Common Stock for resale by the selling stockholders. The registration covers (i) 37,174,713 shares issuable upon exercise of pre-funded warrants and (ii) 37,174,713 shares issuable upon exercise of common warrants issued in a March 31, 2026 private placement. We are not offering any shares for sale ourselves and will not receive proceeds from resales; we will receive cash proceeds only if outstanding warrants are exercised for cash. The exercise prices are $0.001 for the pre-funded warrants and $0.683 for the common warrants; the common warrants expire December 31, 2029, subject to certain terms. Shares outstanding were 11,982,776 as of March 31, 2026. The registration permits public or private resales by the listed selling holders, including transfers to successors, and includes beneficial ownership blockers limiting exercises to 4.99% (or, at holder election, 9.99%) ownership.
Aprea Therapeutics is registering for resale 12,577,714 shares of Common Stock to permit selling stockholders to resell shares issued in a January 2026 private placement.
The registration covers (i) 1,877,677 shares issued in the Private Placement, (ii) 4,411,180 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.001, and (iii) 6,288,857 shares issuable upon exercise of common warrants at an exercise price of $0.765. The company will receive no proceeds from resale transactions, but will receive cash if warrants are exercised for cash.
Shares outstanding were 11,451,118 as of January 30, 2026. The prospectus discloses a Nasdaq listing under the symbol APRE and a March 18, 2026 last reported sale price of $0.7311.
Aprea Therapeutics, Inc. is registering 5,503,556 shares of common stock for potential resale by investors from a December 2025 private placement and related warrants. The shares consist of 26,459 already issued shares, 2,596,564 shares underlying pre-funded warrants, 2,623,023 shares underlying common warrants, and 257,510 warrant shares issued to Maxim Group LLC as compensation. Aprea will not receive proceeds from any resale, but may receive cash if warrants are exercised at $1.04 or $0.001 per share, which it plans to use for clinical trials, working capital and general corporate purposes. The registered securities represent about 79% of the 6,993,838 shares outstanding as of December 10, 2025, creating potential selling pressure on the stock. Aprea is a clinical-stage oncology company developing synthetic lethality therapies, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, both in early-stage clinical development.